Gilead Q3 adjusted EPS $2.55 beats estimate, sales beat; FY outlook a loss on acquired R&D charges

Gilead Sciences reported Q3 adjusted EPS of $2.55, beating the $2.19 estimate, on product sales of $8.289B. The company guided FY product sales of $31B-$31.3B and an adjusted loss per share of $0.85-$1.20 on acquired R&D charges.

Detected & updated continuously · Source: Nebula